Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Melanoma 21Carcinoma, Renal Cell 18HIV Infections 6Acquired Immunodeficiency Syndrome 6Sarcoma, Kaposi 5Leukemia 5Neoplasm Metastasis 4Lymphoma 4Leukemia, Myelogenous, Chronic, BCR-ABL Positive 4Triple Negative Breast Neoplasms 3Recurrence 3Neoplasms 3Kidney Neoplasms 3Hematologic Neoplasms 3Precursor Cell Lymphoblastic Leukemia-Lymphoma 2Pancreatic Neoplasms 2Mycosis Fungoides 2Multiple Myeloma 2Leukemia, Myeloid, Chronic-Phase 2Colorectal Neoplasms 2Breast Neoplasms 2Brain Neoplasms 2Uveal Melanoma 1Uterine Cervical Neoplasms 1Uterine Cervical Dysplasia 1Urinary Bladder Neoplasms 1Urethral Neoplasms 1Tumor Virus Infections 1Thrombocythemia, Essential 1Solid Cancers 1

Interventions

Microscopy, Confocal 2Indocyanine Green 2Everolimus 2varlilumab 1Ultrasonography 1Sunitinib 1Simvastatin 1Radiosurgery 1Palliative Care 1Neoadjuvant Therapy 1Narrow Band Imaging 1Interferon alpha-2 1IFL protocol 1Gastrectomy 1Folfox protocol 1Endoscopic Mucosal Resection 1Drug Delivery Systems 1Drug Combinations 1Dermoscopy 1Chemoradiotherapy 1Bevacizumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Interventional × Margins of Excision × Interferon alpha-2 × Clear all
NCT00719264 2017-03-20

Safety and Efficacy of Bevacizumab Plus RAD001 Versus Interferon Alfa-2a and Bevacizumab for the First-line Treatment in Adult Patients With Kidney Cancer

Novartis

Phase 2 Completed
365 enrolled 14 charts
Genitourinary

Margins of Excision, Adenocarcinoma, Carcinoma, Carcinoma, Renal Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡